The synthetic peptide [D-Arg1,D-Pro2,D-Trp7'9,Leu'1]substance P inhibits the stimulation of DNA synthesis induced in Swiss 3T3 cells by bombesin or vasopressin, but not that induced by a wide range of other growth factors and mitogens. The stimulation induced by 10 pM-3 nM-bombesin is inhibited by 1-30 ,IM-antagonist in a manner consistent with competition at the bombesin receptor. The inhibition by the antagonist of the stimulation induced by vasopressin suggests a previously unrecognized interaction of the antagonist with vasopressin receptors. The antagonist should be useful in studies of cell proliferation both in vivo and in vitro.
INTRODUCTION
The frog skin-derived tetradecapeptide bombesin, and related peptides present in mammalian tissues including gut (Bloom et al., 1979; Walsh et al., 1979) brain (Brown et al., 1978; Moody & Pert, 1979; Walsh et al., 1979) , tumour cells (Moody et al., 1981; Wood et al., 1981; Erisman et al., 1982) and milk (Jahnke & Lazarus, 1984; Ekman et al., 1985) , elicit a wide range of cellular responses in vivo and in vitro, including the stimulation of cell proliferation (Carney et al., 1983; Rozengurt & Sinnett-Smith, 1983; Willey et al., 1984) . The investigation ofthe biochemical mechanisms involved in the stimulation of cell proliferation by bombesin or other growth factors would be aided by the availability of specific antagonists. Recently, a substance P analogue ([D-Arg',D-Pro2,DTrp7 9,Leu11]substance P) has been demonstrated to be a competitive antagonist of the binding of bombesin to its receptors on pancreatic acinar cells (Jensen et al., 1984) . We now show here that this peptide inhibits the mitogenic stimulation of Swiss 3T3 cells by bombesin. The specificity of this inhibition is indicated by the lack of effect of the peptide on the stimulation induced by a wide range of other growth factors and mitogens. In platelet-derived growth factor were prepared as described previously (Savage & Cohen, 1972; . Methods Stock cultures of Swiss mouse 3T3 cells were maintained and passaged as described previously . For experimental use cells were seeded into 24-well cluster trays (Nunc) at 12 500 cells/well and grown for 7 days, by which time they were confluent (at about 60000 cells/well) and quiescent (as judged by the incorporation of [3H]thymidine). Each well was rinsed with 0.5 ml of serum-free Dulbecco's modified Eagle's medium before adding 0.5 ml of this medium containing
[3H]thymidine (1 #tCi/ml; 1 I/M) either with or without 0.5 jug of insulin/ml. The cells were then incubated for 30 min at 37°C with the indicated concentration of antagonist or substance P, which were added at 20 ll/well from dilutions prepared in Dulbecco's modified Eagle's medium containing 1 mg of defatted bovine serum albumin/ml; control wells received the same volume addition of this medium. Mitogens were then added from dilutions prepared in the same way. After incubation for 28 h at 37°C, the trichloroacetic acid-insoluble radioactivity was determined as described previously .
RESULTS AND DISCUSSION
In common with other mitogens that stimulate the proliferation of Swiss 3T3 cells, bombesin has limited mitogenic activity when added alone, but produces a marked synergistic stimulation with insulin or insulin-like growth factors (Rozengurt, 1980; Jiminez de Asua et al., 1981; Rozengurt & Sinnett-Smith, 1983) . Thus, in the presence of insulin, significant stimulation of [3H]thymidine incorporation by Swiss 3T3 cells was induced by 10-30 pM-bombesin and maximal stimulation by bombesin concentrations of 1 nm and above (Fig. la (Fig. la) . The effectiveness of the antagonist was dose-dependent: in five separate experiments the stimulation induced by 100 pM-bombesin was half-maximally inhibited by between 3 and 10 ,uM-antagonist, and 30 uMantagonist gave 82-90 % inhibition (Fig. I b) . This pattern of antagonism is similar to that previously demonstrated against bombesin-induced amylase secretion from pancreatic acini (Jensen et al., 1984) . The antagonist itself had no mitogenic activity when added alone or in combination with insulin, and it did not inhibit the small stimulation of [3H]thymidine incorporation induced by insulin alone (Fig. lb) . polyphosphoinositide turnover . The exposure of Swiss 3T3 cells to bombesin results in a rapid increase in the breakdown of phosphatidylinositol 4,5-bisphosphate to inositol 1,4,5-trisphosphate and diacylglycerol , both of which are potential second messengers (Berridge, 1984; Irvine et al., 1984; Nishizuka, 1984) : inositol 1 ,4,5-trisphosphate induces the release of Ca2+ from intracellular stores Irvine et al., 1984) , and diacylglycerol is a potent activator of protein kinase C (Nishizuka, 1984) . Several other stimulators of the proliferation of Swiss 3T3 cells (vasopressin, platelet-derived growth factor and prostaglandin F2.) have also been found to stimulate phosphatidylinositol 4,5-bisphosphate breakdown and raise the intracellular free [Ca2+] in these cells Brown et al., 1984; Moolenaar et al., 1984; Morris et al., 1984) . The specificity of the antagonist was therefore tested by using these and other mitogens at concentrations that, in the presence of insulin, induced stimulations similar to that obtained with 100 pMbombesin (Table 1 ). The antagonist (30 #M) had no effect on the stimulation induced by epidermal growth factor, platelet-derived growth factor or prostaglandin F2a, or by phorbol 12-myristate 13-acetate (a potent activator of protein kinase C; Nishizuka, 1984 , 1984) . Substance P (1 nM-30 pM) had no mitogenic activity on these cells (Fig. lb) , did not affect the stimulation of DNA synthesis by any combination of mitogens tested (Fig. Ib, and other results not shown), and did not prevent the inhibitory action of the antagonist against bombesin-induced stimulation (Table  1) .
While examining the specificity of the antagonist, we noted that it consistently inhibited the stimulation of Swiss 3T3 cells by vasopressin (Table 1) . Again, this inhibition is unlikely to be due to non-specific post-receptor effects of the antagonist, since the stimulations induced by platelet-derived growth factor and prostaglandin F2, were not inhibited (Table 1) . Rather, the antagonist appears to act in a competitive manner against the stimulation induced by vasopressin, as illustrated by a shift in the vasopressin dose-response curve (Fig. 2) . The structural basis of this antagonism is not obvious from the sequences of the peptides: it would be interesting both to examine the effects of the antagonist on other vasopressin-induced cellular responses and to compare the actions of this antagonist with those of other vasopressin antagonists described previously (Jard, 1983; Manning & Sawyer, 1983) .
The demonstration that
Trp7 9,Leu11]substance P acts as an antagonist of the bombesin-induced stimulation of DNA synthesis in Swiss 3T3 cells, as well as antagonizing bombesin-mediated amylase secretion from pancreatic acini (Jensen et al., 1984) , confirms its potential for use in studies of the interaction of bombesin with its receptors, and of the signalling mechanisms controlling the consequent intracellular responses. This antagonist will be especially useful in studies of cell-growth control, since very few specific antagonists of peptides promoting cell proliferation have been described, and bombesin is a very potent stimulator of the proliferation of Swiss 3T3 cells (Rozengurt & Sinnett-Smith, 1983) . A further use for the antagonist may be in the investigation of bombesin-or vasopressin-like bioactivity in tissue extracts and body fluids. Finally, bombesin stimulates the proliferation of various cell types other than Swiss 3T3 cells (Carney et al., 1983; Willey et al., 1984) , and it has been suggested that bombesin-related peptides may function as autocrine factors in stimulating the growth of a variety of tumours that contain and may secrete these peptides Price et al., 1985; Sporn & Roberts, 1985) . It should be interesting to determine whether the growth of such tumours can be inhibited by exposure to the bombesin antagonist.
